because pmea has stronger in vivo antiretrovirus potency and selectivity than azidothymidine and various other compounds currently being subjected to clinical trials , pmea studies should be pursued to assess the potential of this compound in the treatment of acquired immunodeficiency syndrome ( aids ) and other retrovirus infections in humans .
C0043474
azidothymidine
C0001175
acquired